Research output per year
Research output per year
Personal profile
Expertise related to UN Sustainable Development Goals
In 2015, UN member states agreed to 17 global Sustainable Development Goals (SDGs) to end poverty, protect the planet and ensure prosperity for all. This person’s work contributes towards the following SDG(s):
Fingerprint
Dive into the research topics where Henkjan Verkade is active. These topic labels come from the works of this person. Together they form a unique fingerprint.
- 1 Similar Profiles
Collaborations and top research areas from the last five years
Recent external collaboration on country/territory level. Dive into details by clicking on the dots or
-
Genome-wide meta-analysis associates donor-recipient non-HLA genetic mismatch with acute cellular rejection post-liver transplantation
TransplantLines Investigators, Nieuwenhuis, L. M., Li, Y., Loza, B.-L., Lambeck, A. J. A., Hu, S., Gacesa, R., Voskuil, M. D., Hepkema, B. G., Jansen, B. H., Blokzijl, H., Verkade, H.-J., van den Heuvel, M. C., Asrani, S., Testa, G., Klintmalm, G., Trotter, J., Olthoff, K. M., Shaked, A. & Keating, B. J. & 3 others, , Jan-2025, In: Hepatology communications. 9, 1, 15 p., e0601.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile13 Downloads (Pure) -
Molecular adsorbent recirculating system (MARS®) and continuous renal replacement therapy for the treatment of paediatric acute liver failure: two-centre retrospective cohort study
Saxena, R., Alexander, E. C., Bontemps, S., Singla, R., Verkade, H. J., de Meijer, V. E., Kneyber, M. C. J. & Deep, A., Mar-2025, In: European Journal of Pediatrics. 184, 3, 11 p., 192.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile5 Downloads (Pure) -
Obtaining first-line induction in autoimmune hepatitis: Aren't we underestimating prednisolone?
Loeffen, E. A. H., Verkade, H. J. & van Rheenen, P. F., Feb-2025, In: Journal of Hepatology. 82, 2, p. e78 1 p.Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review
Open AccessFile1 Citation (Scopus)6 Downloads (Pure) -
Sleep duration among breastfed, goat milk-based or cow's milk-based infant formula-fed infants: Post hoc analyses from a double-blind RCT
van Lee, L., Meijer-Krommenhoek, Y., He, T., van der Zee, L. & Verkade, H., Mar-2025, In: Journal of Pediatric Gastroenterology and Nutrition. 80, 3, p. 482-489 8 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile1 Citation (Scopus)1 Downloads (Pure) -
EASL Clinical Practice Guidelines on genetic cholestatic liver diseases
European Association for the Study of the Liver, Aug-2024, In: Journal of Hepatology. 81, 2, p. 303-325 23 p.Research output: Contribution to journal › Article › Academic › peer-review
Open AccessFile7 Citations (Scopus)31 Downloads (Pure)
Activities
-
Medical treatment in sclerosing cholangitis: What works and what doesn’t?
Verkade, H. (Speaker)
6-May-2022Activity: Talk and presentation › Professional or public presentation › Professional
-
Introduction to the NAPPED Consortium
Verkade, H. (Invited speaker)
29-Apr-2022Activity: Talk and presentation › Professional or public presentation › Professional
-
Improving the prognosis of very rare diseases: what an individual professional or center can do.
Verkade, H. (Invited speaker)
8-Dec-2022Activity: Talk and presentation › Academic presentation › Academic
-
Effects on Serum Bile Acids, Pruritus, and Safety With Up to 72 Weeks of Odevixibat Treatment: Pooled Data From the PEDFIC 1 and PEDFIC 2 Studies in Children With Progressive Familial Intrahepatic Cholestasis
Verkade, H. (Invited speaker)
29-Apr-2022Activity: Talk and presentation › Professional or public presentation › Professional
-
Networking and international registries in rare pediatric lever diseases: the example of the NAPPED registry.
Verkade, H. (Keynote speaker)
1-Dec-2022Activity: Talk and presentation › Academic presentation › Academic
Press/Media
-
Drugs, approval in the EU of 2 new therapies for rare cholestatic diseases
27/09/2024
1 Media contribution
Press/Media: Expert Comment › Popular
-
Ipsen crosses EU finish line with Alagille syndrome drug
24/09/2024
1 Media contribution
Press/Media: Expert Comment › Popular
-
Ipsen’s Kayfanda® (odevixibat) approved in European Union for cholestatic pruritus in Alagille Syndrome, a rare liver disease
24/09/2024
1 item of Media coverage
Press/Media: Expert Comment › Popular
-
Ipsen’s Kayfanda® Approved in European Union for Rare Liver Disease
24/09/2024
1 Media contribution
Press/Media: Expert Comment › Popular
-
Ipsen today announced that the European Commission has approved Kayfanda® (odevixibat) under exceptional circumstances for the treatment of cholestatic pruritus in Alagille Syndrome (ALGS) in patients aged 6 months or older - Ipsen.com
24/09/2024
1 item of Media coverage
Press/Media: Expert Comment › Popular